CA2835967A1 - Papaya mosaic virus compositions and uses thereof for stimulation of the innate immune response - Google Patents

Papaya mosaic virus compositions and uses thereof for stimulation of the innate immune response Download PDF

Info

Publication number
CA2835967A1
CA2835967A1 CA2835967A CA2835967A CA2835967A1 CA 2835967 A1 CA2835967 A1 CA 2835967A1 CA 2835967 A CA2835967 A CA 2835967A CA 2835967 A CA2835967 A CA 2835967A CA 2835967 A1 CA2835967 A1 CA 2835967A1
Authority
CA
Canada
Prior art keywords
papmv
infection
subject
virus
vlps
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA2835967A
Other languages
English (en)
French (fr)
Inventor
Denis Leclerc
Alain Lamarre
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Institut National de La Recherche Scientifique INRS
Folia Biotech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Institut National de La Recherche Scientifique INRS, Folia Biotech Inc filed Critical Institut National de La Recherche Scientifique INRS
Publication of CA2835967A1 publication Critical patent/CA2835967A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A61P31/06—Antibacterial agents for tuberculosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/10011—Arenaviridae
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/26011—Flexiviridae
    • C12N2770/26023—Virus like particles [VLP]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/26011—Flexiviridae
    • C12N2770/26034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/26011—Flexiviridae
    • C12N2770/26041—Use of virus, viral particle or viral elements as a vector
    • C12N2770/26042—Use of virus, viral particle or viral elements as a vector virus or viral particle as vehicle, e.g. encapsulating small organic molecule
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Virology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
CA2835967A 2011-05-13 2012-05-01 Papaya mosaic virus compositions and uses thereof for stimulation of the innate immune response Abandoned CA2835967A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201161485955P 2011-05-13 2011-05-13
US61/485,955 2011-05-13
PCT/CA2012/050278 WO2012155261A1 (en) 2011-05-13 2012-05-01 Papaya mosaic virus compositions and uses thereof for stimulation of the innate immune response

Publications (1)

Publication Number Publication Date
CA2835967A1 true CA2835967A1 (en) 2012-11-22

Family

ID=47176093

Family Applications (2)

Application Number Title Priority Date Filing Date
CA2835967A Abandoned CA2835967A1 (en) 2011-05-13 2012-05-01 Papaya mosaic virus compositions and uses thereof for stimulation of the innate immune response
CA2835972A Abandoned CA2835972A1 (en) 2011-05-13 2012-05-01 Virus-like particles and process for preparing same

Family Applications After (1)

Application Number Title Priority Date Filing Date
CA2835972A Abandoned CA2835972A1 (en) 2011-05-13 2012-05-01 Virus-like particles and process for preparing same

Country Status (11)

Country Link
US (2) US20140154288A1 (https=)
EP (2) EP2707027A4 (https=)
JP (2) JP6093926B2 (https=)
CN (2) CN103687942A (https=)
AU (1) AU2012255595A1 (https=)
BR (2) BR112013029144A2 (https=)
CA (2) CA2835967A1 (https=)
DK (1) DK2707480T3 (https=)
MX (1) MX2013013228A (https=)
NO (1) NO2800866T3 (https=)
WO (2) WO2012155261A1 (https=)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20140154288A1 (en) 2011-05-13 2014-06-05 Folia Biotech Inc. Papaya mosaic virus compositions and uses thereof for stimulation of the innate immune response
US20160228541A1 (en) * 2013-09-19 2016-08-11 Alain Lamarre Papaya mosaic virus and virus-like particles in cancer therapy
US11998594B2 (en) 2014-04-02 2024-06-04 Case Western Reserve University Anti-cancer plant virus particles linked to HER2 antigens
WO2015153883A1 (en) 2014-04-02 2015-10-08 Case Western Reserve University Vaccination using plant virus particles linked to her2 antigens
CN107002085A (zh) * 2014-09-11 2017-08-01 卡迪拉保健有限公司 具有优异免疫学特性的优异的人乳头瘤病毒抗原和含有其的疫苗
WO2016127262A1 (en) * 2015-02-12 2016-08-18 Folia Biotech Inc. Multimerized orthomyxovirus nucleoprotein and uses thereof
GB201708709D0 (en) 2017-06-01 2017-07-19 Univ York Virus like particle
MX385484B (es) * 2017-06-28 2025-03-14 Univ Mexico Nac Autonoma Vlps derivadas de virus de planta con dsrna encapsidado y metodo de sintesis.
FR3106648B1 (fr) * 2020-01-28 2022-05-27 Arkema France Structure multicouche pour le transport ou le stockage de l’hydrogene

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5443969A (en) 1992-10-29 1995-08-22 Rutgers University RNA packaging system
US8101189B2 (en) 2002-07-05 2012-01-24 Folia Biotech Inc. Vaccines and immunopotentiating compositions and methods for making and using them
ES2431963T3 (es) 2002-07-05 2013-11-28 Folia Biotech Inc. Partícula viral adyuvante
RU2375076C2 (ru) 2003-07-10 2009-12-10 Цитос Биотехнологи Аг Укомплектованные вирусоподобные частицы
WO2005042017A1 (en) 2003-10-22 2005-05-12 Id Biomedical Corporation Of Quebec Compositions and methods for activating innate and allergic immunity
CA2669485C (en) 2006-11-15 2017-01-03 Folia Biotech Inc. Papaya mosaic virus-based vaccines for influenza
JP2010508857A (ja) 2006-11-15 2010-03-25 フォリア バイオテック インコーポレイテッド パパイヤモザイクウイルスに基づく免疫原性の親和性で複合体化された抗原系及びその使用
US7799281B2 (en) 2007-01-16 2010-09-21 Festo Corporation Flux concentrator for biomagnetic particle transfer device
US20100316665A1 (en) 2007-01-26 2010-12-16 Denis Leclerc Papaya mosaic virus-based vaccines against salmonella typhi and other enterobacterial pathogens
WO2010012069A1 (en) 2008-07-30 2010-02-04 Folio Biotech Inc. Multivalent vaccines based on papaya mosaic virus and uses thereof
WO2010030790A2 (en) 2008-09-10 2010-03-18 The Texas A&M University System Methods and compositions for stimulation of mammalian innate immune resistance to pathogens
US20140154288A1 (en) 2011-05-13 2014-06-05 Folia Biotech Inc. Papaya mosaic virus compositions and uses thereof for stimulation of the innate immune response

Also Published As

Publication number Publication date
EP2707027A4 (en) 2015-06-03
JP2014514350A (ja) 2014-06-19
DK2707480T3 (da) 2017-11-13
JP2014519817A (ja) 2014-08-21
MX2013013228A (es) 2013-12-12
WO2012155262A1 (en) 2012-11-22
EP2707480A1 (en) 2014-03-19
NO2800866T3 (https=) 2018-04-14
CA2835972A1 (en) 2012-11-22
EP2707480A4 (en) 2015-01-07
AU2012255595A1 (en) 2013-12-12
CN103687942A (zh) 2014-03-26
US20140255439A1 (en) 2014-09-11
CN103648528A (zh) 2014-03-19
BR112013029144A2 (pt) 2017-07-11
JP6093926B2 (ja) 2017-03-15
WO2012155261A1 (en) 2012-11-22
BR112013029143A2 (pt) 2017-07-11
JP6213461B2 (ja) 2017-10-18
EP2707027A1 (en) 2014-03-19
US20140154288A1 (en) 2014-06-05
US9833504B2 (en) 2017-12-05
EP2707480B1 (en) 2017-08-02

Similar Documents

Publication Publication Date Title
US20140154288A1 (en) Papaya mosaic virus compositions and uses thereof for stimulation of the innate immune response
De Filette et al. The universal influenza vaccine M2e-HBc administered intranasally in combination with the adjuvant CTA1-DD provides complete protection
CN108348593B (zh) 基于人呼吸道合胞病毒(hrsv)病毒样颗粒(vlps)的疫苗
JP2014520117A5 (https=)
JP2016517414A (ja) インフルエンザ核酸分子及びそれから作製したワクチン
JP2013517800A (ja) インフルエンザ核酸分子及びそれから作製したワクチン
JP2023518340A (ja) 鼻腔内ｍＲＮＡワクチン
Li et al. Advances and prospects of respiratory mucosal vaccines: mechanisms, technologies, and clinical applications
WO2022080414A1 (ja) ベータコロナウイルス温度感受性株及びワクチン
WO2022233629A1 (en) Sars-cov-2 subunit vaccine
US20230355740A1 (en) Compositions and methods of use thereof for prevention and treatment of influenza infections
US20180250602A1 (en) Papaya mosaic virus compositions and uses thereof for stimulation of the innate immune response
KR20230041775A (ko) 인플루엔자 바이러스 백본
AU2012255594A1 (en) Papaya Mosaic Virus compositions and uses thereof for stimulation of the innate immune response
Dehari et al. RNA-Based Vaccines for Infectious Disease
EP4333883A2 (en) Sars-cov-2 subunit vaccine
Rekstin et al. Early protective effect of live influenza vaccine against homologous and heterologous influenza infection at different times after immunization
US20240335522A1 (en) Multivalent pan-influenza vaccine
WO2017123932A1 (en) Inactived vaccine for chikungunya virus
Falkeborn et al. Comparison of the mucosal adjuvant Endocine™ with two well-known adjuvants: Cholera toxin and alum
Yu et al. Measles virus infection: mechanisms of immune suppression
HK40085781A (en) Intranasal mrna vaccines
HK1259274B (en) Human respiratory syncytial virus (hrsv) virus-like particles (vlps) based vaccine
WO2002011761A2 (en) Vaccine against rsv
Hickey et al. Prospects in nasal vaccination against clinically relevant pathogens and select agents

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20180501

FZDE Discontinued

Effective date: 20200831